4 scientists explain what attracted them to cancer drug development

"From the bench to the bedside" is a phrase often used to describe the drug discovery journey from the lab to the clinic. MD Anderson's Therapeutics Discovery division, however, takes a different approach, by beginning with the bench at the bedside. This cancer drug discovery engine conducts research that is influenced by patients from the very start. "We are completely driven by the unmet treatment needs we see in patients who come to MD Anderson for help," says Phil Jones, Ph.D., vice president of Therapeutics Discovery. "Guided by the expertise of our world-class clinicians, our efforts begin with the patient and their cancer." The benefits of an in-house cancer drug discovery model Composed of three Moon Shots Program™ platforms and the Neurodegeneration Consortium, Therapeutics Discovery is working hard to bring life-saving medicines to patients quickly, safely and effectively. These medicines range from new chemical compounds to antibodies and cell-based therapies. Unlike typical pharmaceutical companies, Therapeutics Discovery was built here at MD Anderson, reducing the time it takes for a new drug to start benefitting our cancer patients. It's a recipe for success that is already yielding promising treatment results. And at the heart of it all are more than 100 scientists, driven by a passion to see their work one day save a patient's life. Inventing new ways to treat cancer and help patients The Institute for Applied Cancer Science (IACS) is devoted to inventing new small-molecule drugs, or chemical compounds, that target specific vulnerabilities in cancer cells. Mick Soth, Ph.D., is a lead chemist for one of IACS’ drug discovery projects. He’s responsible for designing the safest and...